Neutralizing the Threat

Pan-Ebolavirus Antibodies Close the Loop

Research output: Contribution to journalShort survey

6 Citations (Scopus)

Abstract

The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.

Original languageEnglish (US)
Pages (from-to)669-671
Number of pages3
JournalTrends in Molecular Medicine
Volume23
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Ebolavirus
Antiviral Agents
Glycoproteins
Vaccines
Membrane Fusion
Antibodies
Animal Models
Monoclonal Antibodies
Infection

Keywords

  • antibody
  • Bundibugyo
  • Ebolavirus
  • Sudan
  • treatment
  • Zaire

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Neutralizing the Threat : Pan-Ebolavirus Antibodies Close the Loop. / Mire, Chad; Geisbert, Thomas.

In: Trends in Molecular Medicine, Vol. 23, No. 8, 01.08.2017, p. 669-671.

Research output: Contribution to journalShort survey

@article{5b06ed6a736e452888af9127f30b5b50,
title = "Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop",
abstract = "The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.",
keywords = "antibody, Bundibugyo, Ebolavirus, Sudan, treatment, Zaire",
author = "Chad Mire and Thomas Geisbert",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.molmed.2017.06.008",
language = "English (US)",
volume = "23",
pages = "669--671",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Neutralizing the Threat

T2 - Pan-Ebolavirus Antibodies Close the Loop

AU - Mire, Chad

AU - Geisbert, Thomas

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.

AB - The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.

KW - antibody

KW - Bundibugyo

KW - Ebolavirus

KW - Sudan

KW - treatment

KW - Zaire

UR - http://www.scopus.com/inward/record.url?scp=85022087390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022087390&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2017.06.008

DO - 10.1016/j.molmed.2017.06.008

M3 - Short survey

VL - 23

SP - 669

EP - 671

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 8

ER -